Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.56 USD | +4.81% | -0.86% | +119.77% |
Apr. 29 | Stoke Therapeutics Appoints Thomas Leggett CFO | MT |
Apr. 29 | Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024 | CI |
Evolution of the average Target Price on Stoke Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Stoke Therapeutics, Inc.
TD Cowen | |
Canaccord Genuity | |
Wedbush | |
Needham & Co. | |
JPMorgan Chase | |
Cantor Fitzgerald | |
BofA Securities | |
Credit Suisse | |
HC Wainwright | |
Jefferies & Co. | |
UBS |
EPS Revisions
- Stock Market
- Equities
- STOK Stock
- Consensus Stoke Therapeutics, Inc.